#None #financial results #medical cannabis #IM Cannabis

IM Cannabis' Significant Financial Progress in Q4 2024

The international medical cannabis industry is witnessing major shifts, and IM Cannabis Corp. is increasingly leading this transformation. Recently, the company reported its financial outcomes for the fourth quarter and the entire year ending on December 31, 2024. With encouraging results, IM Cannabis demonstrated considerable growth and improved operational efficiencies.

Financial Highlights

In the last quarter of 2024, IMC's revenue surged by an impressive 25% compared to the same quarter in the previous year, totaling $13.3 million. Over the entire year, the company realized an 11% increase in revenue, reaching $54 million as compared to $48.8 million in 2023. These figures highlight IMC's successful expansion strategies, particularly in Germany, where revenues skyrocketed 183%, generating $15.5 million versus $5.5 million the previous year.

In conjunction with this revenue growth, IM Cannabis achieved an adjusted EBITDA profit of $0.5 million in Q4 2024, reversing from a notable loss of $4.3 million in the same timeframe last year. This marked an 87% reduction in operating losses over the year, down to $1.1 million from $8 million in 2023. The company's commitment to cost efficiency is evident, with a 42% decrease in operational expenses compared to the fourth quarter of 2023.

Operational Improvements

As Oren Shuster, CEO of IM Cannabis Corp., expressed, the 183% growth in Germany is a significant milestone. However, the company made strides internally as well, with a strong focus on strategic operational improvements leading to increased profitability. Shuster commented on the positive adjusted EBITDA achieved in Q4, which not only indicates savings from cost management initiatives but also signifies a robust foundation for further growth in 2025.

Revenue Breakdown

Several factors contributed to IM Cannabis's improved financial situation. Notably, revenue from operations in Germany showed remarkable growth, counteracting a $4.8 million revenue decrease from Israel due to the cancellation of the Oranim deal, resulting in a $8.5 million revenue drop compared to the previous year. Nonetheless, the substantial growth in the German market played a crucial role in offsetting these losses, demonstrating the effectiveness of IM Cannabis' strategic pivot towards higher-value markets.

The gross profit figures indicate challenges to overcome as well. In 2024, gross profits fell to $8.5 million, down 14% from last year's $9.8 million, attributed greatly to a one-time inventory clearance costing around $3.8 million. However, the company’s focus on operational efficiency, with general and administrative expenses significantly reduced to $8 million, speaks volumes about its ability to streamline operations and reduce excess spending.

Looking Forward

Management expressed optimism about the upcoming year, indicating Q1 2025 may be the best sales quarter to date for the company in Germany, even with the prevailing challenges that the company faces on the global front such as potential regulatory hurdles and market fluctuations. The financial results unveiled in the conference demonstrate a turning point for IM Cannabis, showcasing a resilient approach amidst various obstacles.

In the long run, with a focus on successfully maneuvering through unique market dynamics and solidifying operational practices, IM Cannabis aims to establish itself as a key player in the global medical cannabis industry.

Investors and interested stakeholders can access IM Cannabis's full financial report and associated documents through the company's official website. As the company prepares for further growth and expansion into new territories, all eyes will remain on IM Cannabis and its forthcoming developments on this exciting front.

• ---